# Opevesostat

Source: https://onco.cc/drugs/opevesostat/  
OnCo record `opevesostat` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Opevesostat is an experimental small-molecule drug from Merck Sharp & Dohme in phase 3 trials for prostate cancer, with its target not yet stated publicly.

## Summary

Opevesostat (MK-5684, ODM-208) is a small-molecule drug developed by Merck Sharp & Dohme. Its molecular target is not stated in the ClinicalTrials.gov intervention record, and OnCo has not confirmed one from the sponsor's pipeline page. It is the investigational product in 5 recruiting or active industry-led phase 2 and phase 3 interventional cancer trials, including phase 3 studies NCT06136624 (Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003)) and NCT06136650 (A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)), in prostate cancer. The largest, NCT06136650, plans to enrol 1314 participants with primary completion expected 2028-05-10. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.

## Fields

- Kind: Treatment
- Status: phase-3
- Last checked: 2026-09-11
- Tags: pipeline; ctgov-ingest
- Code: MK-5684, ODM-208
- Modality: small molecule
- Mechanism: Mechanism not stated in the ClinicalTrials.gov record or on the sponsor's pipeline page.

## Sources

- ClinicalTrials.gov: trials of Opevesostat: https://clinicaltrials.gov/search?intr=MK-5684

## Connected records

- cancers: [Metastatic castration-resistant prostate cancer](https://onco.cc/cancers/prostate-mcrpc/), [Prostate cancer](https://onco.cc/cancers/prostate/)
- companies: [Merck & Co. (MSD)](https://onco.cc/companies/merck/)
- trials: [A Clinical Study of Ifinatamab Deruxtecan Based Treatment Combinations or as Monotherapy to Treat Metastatic Castrate Resistant Prostate Cancer (mCRPC) (MK-2400-01A/IDeate-Prostate02)](https://onco.cc/trials/nct06863272/), [A Study of MK-5684 in People With Certain Solid Tumors (MK-5684-015/OMAHA-015)](https://onco.cc/trials/nct06979596/), [A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)](https://onco.cc/trials/nct06136650/), [Safety and Pharmacokinetics of ODM-208 in Patients With Metastatic Castration-resistant Prostate Cancer](https://onco.cc/trials/nct03436485/), [Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003)](https://onco.cc/trials/nct06136624/), [Substudy 01A: Safety and Efficacy of Opevesostat (MK-5684)-Based Treatment Combinations or Opevesostat Alone in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-5684-01A)](https://onco.cc/trials/nct06353386/)

---
JSON: https://onco.cc/api/v1/entities/opevesostat.json